@jack_shern

Pediatric Oncologist. Sarcoma translational researcher. Camp Fantastic Superfan. Dad. @NCI_CCR_PedsOnc. #ChildhoodCancer. All comments are my own.

Joined August 2020
  • Tweets20
  • Following471
  • Followers313
19/ Please visit medrxiv.org/cgi/content/shor… for the full story and list of amazing contributors like @bega_murray @bvantine1 and many other twitter-less collaborators!
2
7
461
Children and AYAs with newly diagnosed soft tissue sarcomas who are receiving care at a @COGorg member site are now eligible to enroll in the CCDI Molecular Characterization Initiative. Find out more. cancer.gov/research/areas/ch… #Data4ChildhoodCancer
2
18
5
37
JUST ANNOUNCED: NCI's Childhood Cancer Data Initiative (#CCDI) launches the Molecular Characterization Initiative for #ChildhoodCancer research to foster data sharing through comprehensive cancer analysis. Learn more: go.usa.gov/xzy3k #Data4ChildhoodCancer @NCIResearchCtr
33
10
74
Some fun pictures from virtual Camp Fantastic Tues and Wed. #imwithTravis #TeamTravis #EndNF #ikNowaFighter
1
5
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium ascopubs.org/doi/full/10.120… Excited to report on the results of many years of work and which will impact therapy for patients with rhabdomyosarcoma.

Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International...

PURPOSERhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent disease remains poor, and...

ascopubs.org
1
18
2
35
We're making great progress on @theNCI’s Childhood #CancerData Initiative (CCDI). An important part of the CCDI is the National #ChildhoodCancer Registry (NCCR), which uses 23 registries to identify and follow children and AYAs with cancer in the U.S. cancer.gov/research/areas/ch…
1
9
13
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium ascopubs.org/doi/abs/10.1200…

Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International...

PURPOSERhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent disease remains poor, and...

ascopubs.org
2
1
5
What a great collaborative team @khanjavNCI @ShipleyLab @COGorg working to make progress in #Rhabdomyosarcoma
2
4
Hoping that this work will continue to move molecular and genetic profiling of pediatric tumors into the clinic to improve outcomes for our patients #childhoodcancer
1
3
Every single damn day there is another child like Francesca. A child who dies of cancer. A family who found out their child's cancer returned. A family that just learned their baby has cancer. We aren't doing enough. It makes me so angry we don't treat this like an emergency.
86
358
15
6,212
This is Raylin. She has #DIPG, and wants to meet @itsjojosiwa . I believe in the power of Twitter! Let’s do this! #buggysdreamcometrue
13
97
10
645
Upcoming phase III study of selumetinib in adult patients with NF1 and symptomatic inoperable plexiform neurofibromas #nfcon2021 @NCI_CCR_PedOnc @ChildrensTumor #RareDisease #NCIDTC @NCItreatment
1
2
15
Super excited to share this publication - a 7+ year journey of discovery, started when I was a post-doc and driven home by the exceptional Dr. Biniam Adane in the Stegmaier lab @DFBC_PedCare. Loss of STAG2 rewires Ewing Sarcoma transcriptional programs: authors.elsevier.com/c/1dEna…
11
23
4
114
We are excited to see this work published and hope it will help improve our understanding and clinical management of #RareCancers such as bone and soft-tissue #Sarcoma. Please get in touch if you are interested in collaborating with us!
Elizabeth McKenna@ElizSMcKenna10 Jun 2021
Online now in @CD_AACR: Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with #RareCancers (from the @DKTK_ MASTER Program) @StefanFrohling @DKFZ @NCT_HD @TMO_Heidelberg @uniklinik_hd @NCT_UCC_DD cancerdiscovery.aacrjournals…
16
1
50
Right now, @rtsundby is sharing his research on #neurofibromatosis at the 5th Annual Children's Cancer Foundation's Research Symposium. Local #pediatriccancer researchers will speak LIVE all day today - Join now: huddlearea.com/ccfsymposium
2
1
Excited to share our new preprint identifying the immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types. An effort lead by @neelamsinha05 @Sanjusinha7 🧵 1/13 biorxiv.org/content/10.1101/…

Immune determinants of the association between tumor mutational burden and immunotherapy response...

The FDA has recently approved high tumor mutational burden (TMB), defined by ≥10 mutations/Mb, as a biomarker for the treatment of solid tumors with pembrolizumab, an immune checkpoint inhibitor...

biorxiv.org
1
4
3
25
What a great moment to see Senior Yeva Klingbeil at today’s girls track & field meet. Yeva’s teammates help her across the line in the 4X1 relay. Yeva continues her fight with cancer and we continue to be amazed by her spirit!! @CoachCloutier @ShenNews @Agostinoni_Ron
46
331
130
2,634
📣@danalynnecasey et al. found pediatric sarcomas with TP53 mutations to be associated with a radioresistant phenotype, highlighting the critical need for further investigation of novel therapeutic strategies - published today rdcu.be/ckY85 #Cancergenomics
2
1
6
14/14 In the future, @jack_shern, @AngelaHirbe and @aadel_chaudhuri’s labs’ findings could form the basis for improved early cancer detection and monitoring in high-risk cancer-predisposed populations! @CCFtoday @theNCI @WashUGenetics @WashUDPS @OncoAlert @WashURadOnc #sarcoma
2
5
Load more